All questionsGuidelines: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer1 question · 1 sourceGuidelinesDoes NCCN recommend KEYTRUDA for early-stage triple-negative breast cancer?“NCCN CATEGORY 1 PREFERRED: Pembrolizumab (KEYTRUDA) as Part of a Treatment Option for Certain Patients With High-Risk Early-Stage (Stage II–III) TNBC for Neoadjuvant Followed by Adjuvant Therapy4 Preoperative pembrolizumab (KEYTRUDA) in combination with carboplatin + paclitaxel, followed by preoperative pembrolizumab (KEYTRUDA) in combination with cyclophosphamide + doxorubicin or epirubicin, followed by adjuvant pembrolizumab (KEYTRUDA)4” (opens the source at this quote in a new tab)CopyFlag“Category 1 = Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.4” (opens the source at this quote in a new tab)CopyFlag